1 year return (CAGR)
-69.75%
Evogene Exchange (TA, ILA)
EVGN.TA
1.22
+0.02 (+1.48%)
HealthcareBiotechnology
Loading...
3 year return (CAGR)
-64.94%
5 year return (CAGR)
-58.27%
10 year return (CAGR)
-41.10%
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
19.45M
Price/Sales
14.89
Ent value
17.84M
Price/Book
2.20
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
-23.83%
Trailing P/E
-
PEG
-
Forward P/E
-
EPS growth
-30.33%
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 1.27 |
| Daily high | 1.28 |
| Daily low | 1.21 |
| Daily Volume | 76K |
| All-time high | 128920.00 |
| 1y analyst estimate | 5.50 |
| Beta | 0.70 |
| EPS (TTM) | -0.75 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 5 Mar 2026 |
Downside potential
Loading...
Downside potential data
| EVGN.TA | S&P500 | |
| Current price drop from All-time high | -100.00% | -0.14% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 6 Oct 2026 | 9 Mar 2009 |
| Avg drop from high | -66.25% | -10.66% |
| Avg time to new high | 66 days | 12 days |
| Max time to new high | 3166 days | 1805 days |
News
Evogene and Tel Aviv University’s BCDD have partnered to expedite small-molecule drug discovery originating from Israeli academic research.
July 9, 2026
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational chemistry company focused on the generative design of small molecules for the pharmaceutical and agricultural industries, and the Blav...
July 8, 2026
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a computational biology and chemistry company leveraging artificial intelligence (AI) to discover and develop innovative small-molecule products for the pharm...
June 24, 2026
Despite a significant net loss and revenue decline, Evogene Ltd (EVGN) focuses on strategic partnerships and technological advancements to drive future growth.
May 29, 2026
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announ...
October 6, 2026
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultur...
September 30, 2026
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today respon...
August 31, 2026
VANCOUVER, British Columbia, August 27, 2026--EverGen Infrastructure Corp. ("EverGen" or the "Company") (TSXV: EVGN) (OTCQB: EVGIF), today reported financial results as at and for Q2 2026. All amounts...
August 27, 2026
VANCOUVER, British Columbia, August 26, 2026--EverGen Infrastructure Corp. ("EverGen" or the "Company") (TSXV: EVGN), is pleased to report the voting results from its Annual General Meeting of Shareho...
August 26, 2026
AI-driven computational chemistry platform advances pharma partnerships while cutting cash burn.
August 25, 2026